Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: The Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score

European Heart Journal

Volumn 33, Issue 18, 2012, Pages 2282-2289

  Goliasch, Georg ^a   Kleber, Marcus E ^b   Richter, Bernhard ^a   Plischke, Max ^a   Hoke, Matthias ^a   Haschemi, Arvand ^a   Marculescu, Rodrig ^a   Endler, Georg ^a   Grammer, Tanja B ^b   Pilz, Stefan ^c   Tomaschitz, Andreas ^c   Silbernagel, Günther ^d   Maurer, Gerald ^a   Wagner, Oswald ^a   Huber, Kurt ^e   März, Winfried ^b,c,f   Mannhalter, Christine ^a   Niessner, Alexander ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e WILHELMINEN HOSPITAL   (Austria)

^f SYNLAB ACADEMY   (Germany)

Author keywords

Risk prediction; Risk score; Stable coronary artery disease; Survival

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE; CREATININE; HEMOGLOBIN A1C;

AGE DISTRIBUTION; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHOLINESTERASE BLOOD LEVEL; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION; SURVIVAL RATE;

AGED; AUSTRIA; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84866382284     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs164     Document Type: Article

References (27)

1. Task Force for D, Treatment of Non STSEACSoESoC, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28: 1598-1660.
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326: 242-250.
3. Morrow DA. Cardiovascular risk prediction in patients with stable and unstable coronary heart disease. Circulation 2010;121:2681-2691.
4. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S, Investigators RR. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297: 1197-1206. (Pubitemid 46465728)
5. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL, Walma E, Fitzgerald T, Cooney MT, Dudina A, European Society of Cardiology Committee for Practice G. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28:2375-2414. (Pubitemid 47542237)
6. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005; 143:659-672.
7. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A, Long-Term Intervention with Pravastatin in Ischemic Disease S. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravas-tatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol 2001;38:56-63. (Pubitemid 32613828)
8. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55. (Pubitemid 36044403)
9. Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004;43:576-582. (Pubitemid 38229528)
10. Niessner A, Marculescu R, Haschemi A, Endler G, Zorn G, Weyand CM, Maurer G, Mannhalter C, Wojta J, Wagner O, Huber K. Opposite effects of CX3CR1 receptor polymorphisms V249I and T280M on the development of acute coronary syndrome. A possible implication of fractalkine in inflammatory activation. Thromb Haemost 2005;93:949-954. (Pubitemid 40703868)
11. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J, Group LS. Rationale and design of the LURIC study\a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics 2001;2:S1-S73.
12. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J 2010;31:1237-1247.
13. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassifi-cation and beyond. Stat Med 2008;27:157-172; discussion 207-112. (Pubitemid 351193639)
14. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA, Global Registry of Acute Coronary Events I. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163:2345-2353. (Pubitemid 37310196)
15. Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ 2009;339:b4184.
16. Yan AT, Yan RT, Tan M, Casanova A, Labinaz M, Sridhar K, Fitchett DH, Langer A, Goodman SG. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 2007;28:1072-1078. (Pubitemid 47343862)
17. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91: 2844-2850.
18. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003;108:1664-1672. (Pubitemid 37243650)
19. Bogaty P, Brecker SJ, White SE, Stevenson RN, el-Tamimi H, Balcon R, Maseri A. Comparison of coronary angiographic findings in acute and chronic first presentation of ischemic heart disease. Circulation 1993;87:1938-1946. (Pubitemid 23165637)
20. Vranckx P, Boersma E, Garg S, Valgimigli M, Van Es GA, Goedhart D, Serruys PW. Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. EuroIntervention 2011;7:859-871.
21. Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Munzel TF, Tiret L, Vasan RS, Blankenberg S. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 2010;31:3024-3031.
22. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR Jr, Chaitman BR, Kaiser GC, Alderman E, Killip T III. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 1994;90:2645-2657.
23. Mock MB, Ringqvist I, Fisher LD, Davis KB, Chaitman BR, Kouchoukos NT, Kaiser GC, Alderman E, Ryan TJ, Russell RO Jr, Mullin S, Fray D, Killip T III. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982;66:562-568.
24. Calderon-Margalit R, Adler B, Abramson JH, Gofin J, Kark JD. Butyrylcholinester-ase activity, cardiovascular risk factors, and mortality in middle-aged and elderly men and women in Jerusalem. Clin Chem 2006;52:845-852. (Pubitemid 43673263)
25. Goliasch G, Haschemi A, Marculescu R, Endler G, Maurer G, Wagner O, Huber K, Mannhalter C, Niessner A. Butyrylcholinesterase activity predicts long-term survival in patients with coronary artery disease. Clin Chem 2012;58: 1055-1058.
26. Wang TJ. Multiple biomarkers for predicting cardiovascular events: lessons learned. J Am Coll Cardiol 2010;55:2092-2095.
27. Kooter AJ, Kostense PJ, Groenewold J, Thijs A, Sattar N, Smulders YM. Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741-745.